GlassScriptPhysician profile
Raul J Lopez
NPI 1871859587
$18,256.42
in general payments reported to CMS, 2019-2025
34 companies · $2,911 in 2025
The $2,911 reported for 2025 was more than what 88% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,922 · 2020: $992 · 2021: $2,788 · 2022: $2,281 · 2023: $949 · 2024: $2,413 · 2025: $2,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,496 · Travel and Lodging: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,495.84 |
| Travel and Lodging | $777.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,444.17 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic USA, INC. | $2,397.35 | 2019-2020 | |
| Globus Medical, INC. | $1,746.98 | 2025 | Senza, Omnia |
| Medtronic, INC. | $1,545.95 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Nalu Medical, INC. | $1,297.02 | 2023-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $1,011.16 | 2019-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Genesys Orthopedics Systems, L.L.C. | $793.78 | 2021 | |
| Nevro Corp. | $684.94 | 2019 | |
| Scilex Pharmaceuticals INC. | $602.46 | 2019-2021 | |
| Pfizer INC. | $214.23 | 2019-2024 | |
| Spr Therapeutics, INC | $200.85 | 2024 | Sprint Pns System |
| Abbvie INC. | $196.31 | 2021-2024 | |
| Daiichi Sankyo INC. | $189.80 | 2019-2023 | Injectafer |
| Biodelivery Sciences International, INC. | $168.01 | 2019-2021 | |
| Mdd US Operations, LLC | $162.63 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $73.06 | 2021 | |
| Depuy Synthes Sales INC. | $64.30 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $59.48 | 2025 | |
| Radius Health, INC. | $43.68 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.62 | 2021-2023 | Xifaxan |
| Horizon Therapeutics Plc | $43.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.36 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.00 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.52 | 2021 | |
| Pacira Therapeutics, INC. | $26.87 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $25.93 | 2019 | |
| Stryker Corporation | $23.39 | 2019 | |
| Lundbeck LLC | $18.67 | 2021 | |
| Amgen INC. | $18.07 | 2021 | |
| Redhill Biopharma INC. | $14.44 | 2020 | |
| Relievant Medsystems, INC. | $13.86 | 2023 | Intracept |
| Orthogenrx INC. | $13.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.56 | 2019 | |
| Grt US Holding, INC. | $8.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.